C4 Therapeutics Operating Income Over Time
| CCCC Stock | USD 1.81 0.10 5.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare C4 Therapeutics and related stocks such as Insight Molecular, Sangamo Therapeutics, and Cybin Inc Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMDX | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (5 M) | (8.7 M) | (11.1 M) | (18.8 M) | (15.2 M) | (22.2 M) | (29.7 M) | (53.7 M) | (18 M) | (25.1 M) | (61 M) | (54.9 M) | (52.2 M) |
| SGMO | (318 K) | (35.8 M) | (22.2 M) | (26.7 M) | (26.8 M) | (46.9 M) | (72.6 M) | (56.4 M) | (77.2 M) | (105.2 M) | (129.6 M) | (183.3 M) | (201.3 M) | (274 M) | (104 M) | (93.6 M) | (88.9 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | 1.8 M | (2.2 M) | (19.5 M) | (25.8 M) | (37.4 M) | (36.7 M) | (58.3 M) | (63.4 M) | 116.6 M | (61.1 M) | (61.2 M) | (55.1 M) | (52.3 M) |
| CDXS | (18.8 M) | (15.9 M) | (30.5 M) | (41.1 M) | (19.1 M) | (7.8 M) | (8.6 M) | (23 M) | (11.3 M) | (12.5 M) | (23.9 M) | (22.7 M) | (34.9 M) | (68.1 M) | (58.5 M) | (52.7 M) | (50 M) |
| PEPG | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.4 M) | (1.9 M) | (27.1 M) | (68.3 M) | (84.8 M) | (97.7 M) | (88 M) | (83.6 M) |
| ARMP | (5.4 M) | (3.9 M) | (4 M) | (15 M) | (14.1 M) | (10.2 M) | (23.4 M) | (16.2 M) | (12.5 M) | (19.1 M) | (21.6 M) | (23.8 M) | (36.9 M) | (40.9 M) | (42.4 M) | (38.2 M) | (36.3 M) |
| SAVA | (4.7 M) | (3.5 M) | (3.9 M) | 31.4 M | (12.4 M) | (14.2 M) | (15 M) | (11.9 M) | (6.7 M) | (5 M) | (6.4 M) | (32.9 M) | (80 M) | (106 M) | (141.4 M) | (127.3 M) | (120.9 M) |
| OABI | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (25.6 M) | (35.6 M) | (26.6 M) | (69.4 M) | (74.5 M) | (67.1 M) | (63.7 M) |
| MIST | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (23.8 M) | (57.9 M) | (50.7 M) | (43.1 M) | (59.6 M) | (61.1 M) | (42.1 M) | (37.9 M) | (39.8 M) |
C4 Therapeutics and related stocks such as Insight Molecular, Sangamo Therapeutics, and Cybin Inc Operating Income description
Operating Income is the amount of profit realized from C4 Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of C4 Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| C4 Therapeutics | CCCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 490 Arsenal Way, |
| Exchange | NASDAQ Exchange |
USD 1.81
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.